Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 9:4:7.
doi: 10.1186/s40662-017-0072-z. eCollection 2017.

Topical tacrolimus in anterior segment inflammatory disorders

Samir S Shoughy  1
Affiliations
Review

Topical tacrolimus in anterior segment inflammatory disorders

Samir S Shoughy. Eye Vis (Lond). .

Abstract

Immune mediated inflammatory anterior segment diseases are variable and their management requires intense immunosuppression. Treatment with topical steroids is associated with serious ocular side effects. In order to overcome the potentially blinding complications of topical steroids, immunomodulatory drugs are being used more frequently. Tacrolimus is a calcineurin inhibitor that induces suppression of T lymphocytes activity and reduction of ocular inflammation. Tacrolimus was recently investigated for application in various anterior segment inflammatory disorders. In this review, we will discuss the therapeutic application of topical tacrolimus as a steroid-sparing agent in treating T cell mediated anterior segment inflammation.

Keywords: Immune-mediated; Ocular; T cells; Tacrolimus; Topical.

PubMed Disclaimer

References

    1. Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation. 2004;77(9 Suppl):S41–3. - PubMed
    1. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40:1256–65. - PubMed
    1. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999;135:574–580. doi: 10.1001/archderm.135.5.574. - DOI - PubMed
    1. Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol. 2005;53(2 Suppl 2):S165–S170. doi: 10.1016/j.jaad.2005.04.059. - DOI - PubMed
    1. Shoughy SS, Jaroudi MO, Tabbara KF. Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis. Clin Ophthalmol. 2016;10:643–647. doi: 10.2147/OPTH.S99157. - DOI - PMC - PubMed

LinkOut - more resources